دورية أكاديمية

Serum S100A8/A9 and MMP-9 levels are elevated in systemic lupus erythematosus patients with cognitive impairment

التفاصيل البيبلوغرافية
العنوان: Serum S100A8/A9 and MMP-9 levels are elevated in systemic lupus erythematosus patients with cognitive impairment
المؤلفون: Muñoz-Grajales, Carolina, Barraclough, Michelle L., Diaz-Martinez, Juan P., Su, Jiandong, Bingham, Kathleen, Kakvan, Mahta, Kretzmann, Roberta Pozzi, Tartaglia, Maria Carmela, Ruttan, Lesley, Choi, May Y., Appenzeller, Simone, Marzouk, Sherief, Bonilla, Dennisse, Katz, Patricia, Beaton, Dorcas, Green, Robin, Gladman, Dafna D., Wither, Joan, Touma, Zahi
المصدر: Frontiers in Immunology ; volume 14 ; ISSN 1664-3224
بيانات النشر: Frontiers Media SA
سنة النشر: 2024
المجموعة: Frontiers (Publisher - via CrossRef)
مصطلحات موضوعية: Immunology, Immunology and Allergy
الوصف: Objective Cognitive impairment (CI) is one of the most common manifestations of Neuropsychiatric Systemic Lupus Erythematosus (NPSLE). Despite its frequency, we have a limited understanding of the underlying immune mechanisms, resulting in a lack of pathways to target. This study aims to bridge this gap by investigating differences in serum analyte levels in SLE patients based on their cognitive performance, independently from the attribution to SLE, and exploring the potential for various serum analytes to differentiate between SLE patients with and without CI. Methods Two hundred ninety individuals aged 18-65 years who met the 2019-EULAR/ACR classification criteria for SLE were included. Cognitive function was measured utilizing the adapted ACR-Neuropsychological Battery (ACR-NB). CI was defined as a z-score of ≤-1.5 in two or more domains. The serum levels of nine analytes were measured using ELISA. The data were randomly partitioned into a training (70%) and a test (30%) sets. Differences in the analyte levels between patients with and without CI were determined; and their ability to discriminate CI from non-CI was evaluated. Results Of 290 patients, 40% (n=116) had CI. Serum levels of S100A8/A9 and MMP-9, were significantly higher in patients with CI (p=0.006 and p=0.036, respectively). For most domains of the ACR-NB, patients with CI had higher S100A8/A9 serum levels than those without. Similarly, S100A8/A9 had a negative relationship with multiple CI tests and the highest AUC (0.74, 95%CI: 0.66-0.88) to differentiate between patients with and without CI. Conclusion In this large cohort of well-characterized SLE patients, serum S100A8/A9 and MMP-9 were elevated in patients with CI. S100A8/A9 had the greatest discriminatory ability in differentiating between patients with and without CI.
نوع الوثيقة: article in journal/newspaper
اللغة: unknown
DOI: 10.3389/fimmu.2023.1326751
DOI: 10.3389/fimmu.2023.1326751/full
الإتاحة: https://doi.org/10.3389/fimmu.2023.1326751Test
حقوق: https://creativecommons.org/licenses/by/4.0Test/
رقم الانضمام: edsbas.E59F65C0
قاعدة البيانات: BASE